Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Paul Matteis
STIF
Paul Matteis
Wall Street Analyst
★★★★☆
#483
on 13Foresight · ranked by our own returns
55%
Success Rate
+18.4%
Average Return
23 of 42 calls profitable · +10.4% vs benchmark
📈 Across the calls we could measure, roughly 55% of Paul Matteis's ratings turned a profit when each position was held for 1 year — averaging +18.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

139 Buy 34 Hold 0 Sell
Paul's Stock Coverage 41 ratings · 2026-06-20
Company Date Position Consensus Price Target 1-Yr Return
RYTM
Rhythm Pharmaceuticals
Jun 15, 2026 BUY Strong Buy
+25.2% avg upside
19 analysts
$133.00
37.38% Upside
+6.8%
SPTX
Seaport Therapeutics, Inc.
Jun 09, 2026 BUY Strong Buy
+95.4% avg upside
4 analysts
$30.00
65.10% Upside
·
MPLT
MapLight Therapeutics, Inc.
Jun 02, 2026 BUY Strong Buy
+33.1% avg upside
11 analysts
$36.00
24.90% Upside
-0.7%
IMUX
Immunic
May 28, 2026 BUY Strong Buy
+166.0% avg upside
21 analysts
$25.00
75.96% Upside
-7.4%
SION
Sionna Therapeutics, Inc.
May 25, 2026 BUY Strong Buy
+45.8% avg upside
11 analysts
$55.00
47.41% Upside
-13.0%
BMRN
BioMarin Pharmaceutical
May 24, 2026 HOLD Strong Buy
+72.8% avg upside
52 analysts
$68.00
24.34% Upside
+4.0%
NGNE
Neurogene
May 13, 2026 BUY Buy
+55.5% avg upside
23 analysts
$46.00
45.82% Upside
-15.0%
LXEO
Lexeo Therapeutics, Inc.
May 12, 2026 BUY Strong Buy
+313.8% avg upside
11 analysts
$17.00
244.79% Upside
-10.7%
RAPP
Rapport Therapeutics, Inc.
May 12, 2026 BUY Strong Buy
+45.9% avg upside
12 analysts
$56.00
49.99% Upside
-1.0%
NMRA
Neumora Therapeutics, Inc.
May 12, 2026 HOLD Buy
+422.4% avg upside
11 analysts
$3.00
98.75% Upside
-3.2%
XENE
Xenon
May 08, 2026 BUY Strong Buy
+19.0% avg upside
28 analysts
$86.00
62.49% Upside
-7.2%
CTNM
Contineum Therapeutics, Inc. Class A
May 08, 2026 BUY Strong Buy
+70.7% avg upside
8 analysts
$28.00
134.56% Upside
-11.8%
ALKS
Alkermes
May 08, 2026 BUY Strong Buy
-17.6% avg upside
34 analysts
$45.00
0.02% Upside
+29.6%
ACAD
ACADIA Pharmaceuticals
May 07, 2026 HOLD Strong Buy
+65.9% avg upside
42 analysts
$24.00
10.97% Upside
-4.3%
NBIX
Neurocrine
May 06, 2026 BUY Strong Buy
+7.8% avg upside
37 analysts
$188.00
18.79% Upside
+8.7%
QURE
uniQure
May 05, 2026 BUY Strong Buy
+16.1% avg upside
29 analysts
$28.00
39.50% Downside
+16.8%
VRTX
Vertex Pharmaceuticals
May 05, 2026 HOLD Strong Buy
-2.6% avg upside
61 analysts
$466.00
3.11% Upside
+8.2%
IONS
Ionis Pharmaceuticals
Apr 30, 2026 HOLD Strong Buy
+13.3% avg upside
43 analysts
$86.00
16.05% Upside
-2.0%
DFTX
Definium Therapeutics
Apr 24, 2026 BUY Strong Buy
+44.9% avg upside
20 analysts
$30.00
22.60% Upside
+8.7%
BIIB
Biogen
Apr 04, 2026 BUY Strong Buy
+25.1% avg upside
51 analysts
$214.00
8.91% Upside
+15.3%
PEPG
PepGen Inc.
Apr 04, 2026 BUY Strong Buy
+493.6% avg upside
8 analysts
$12.00
570.37% Upside
-14.8%
ANRO
Alto Neuroscience, Inc.
Apr 02, 2026 BUY Strong Buy
+33.3% avg upside
13 analysts
$33.00
45.05% Upside
-2.4%
DNLI
Denali Therapeutics
Mar 29, 2026 BUY Strong Buy
+60.2% avg upside
24 analysts
$41.00
75.91% Upside
+21.3%
LBRX
LB Pharmaceuticals, Inc.
Mar 27, 2026 BUY Strong Buy
+50.1% avg upside
7 analysts
$40.00
33.26% Upside
+17.0%
CMPS
COMPASS Pathways
Mar 25, 2026 BUY Strong Buy
+63.6% avg upside
18 analysts
$14.00
11.71% Upside
+112.5%
GHRS
GH Research
Mar 06, 2026 BUY Strong Buy
+64.5% avg upside
11 analysts
$32.00
43.80% Upside
+36.2%
VTGN
VistaGen Therapeutics
Feb 13, 2026 HOLD Hold
+287.9% avg upside
8 analysts
$1.00
49.20% Upside
+17.6%
ALNY
Alnylam Pharma
Feb 12, 2026 BUY Strong Buy
+23.6% avg upside
51 analysts
$444.00
59.67% Upside
-8.3%
ALEC
Alector
Dec 22, 2025 HOLD Hold
+532.1% avg upside
14 analysts
+49.0%
ABOS
Acumen Pharmaceuticals
Dec 16, 2025 BUY Strong Buy
+258.9% avg upside
10 analysts
$10.00
342.55% Upside
+11.9%
DYN
Dyne Therapeutics
Dec 15, 2025 BUY Strong Buy
+92.7% avg upside
29 analysts
$36.00
81.82% Upside
+1.1%
LONA
LeonaBio
Sep 19, 2024 HOLD Buy
+13.9% avg upside
9 analysts
-16.8%
CLYM
Climb Bio
Jun 03, 2023 BUY Strong Buy
+57.9% avg upside
18 analysts
$5.00
56.41% Downside
+182.7%
WVE
Wave Life Sciences
May 12, 2022 HOLD Strong Buy
+260.5% avg upside
28 analysts
$3.00
51.36% Downside
+207.8%
IRON
Disc Medicine
Feb 28, 2022 HOLD Strong Buy
+20.2% avg upside
21 analysts
$20.00
71.68% Downside
-38.7%
OBSEF
ObsEva
Aug 16, 2017 BUY Buy
+10799900.0% avg upside
8 analysts
$18.00
17999900.09% Upside
·
NBRVF
Nabriva Therapeutics
Mar 10, 2017 BUY Buy
+13374900.0% avg upside
9 analysts
$20.00
19999900.00% Upside
·
ACIU
AC Immune SA
Nov 23, 2016 BUY Strong Buy
+233.3% avg upside
5 analysts
-1.4%
FATE
Fate Therapeutics
Jun 20, 2016 BUY Buy
+475.7% avg upside
31 analysts
+49.0%
TBPH
Theravance Biopharma
Jun 20, 2016 BUY Buy
+12.2% avg upside
18 analysts
$29.00
74.92% Upside
+70.2%
TPST
Tempest Therapeutics
May 06, 2016 HOLD Buy
+1669.9% avg upside
18 analysts
$7.00
469.06% Upside
-76.3%
🔒 36 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Paul Matteis — Frequently Asked Questions
How accurate are Paul Matteis's stock ratings?
Based on the calls 13Foresight could measure, about 55% of Paul's ratings were profitable over a one-year hold, with an average return of +18.4% per rating, or +10.4% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Paul ranked on 13Foresight?
Paul Matteis is currently ranked #483 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Paul cover?
Paul most recently has ratings on RYTM, SPTX, MPLT, IMUX, SION, BMRN, NGNE, LXEO, RAPP, NMRA, XENE, CTNM and 29 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.